GNMSF News and Press, Genmab A/S Dkk From 08/11/21

Genmab A/S (GMAB) Q2 2021 Results Conference Call August 11, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wim...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q2 earnings call. For further details see: Genmab A/S 2021 Q2 - Results - Earnings Call Presentation

Genmab A/S (NASDAQ:GMAB): Q2 GAAP EPS of DKK4.64. Revenue of DKK1.97B (-63.9% Y/Y). Press Release The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application, for patients with recurrent or metastatic cervical cancer. DARZALEX net sales increas...

BMEZ is a fund focused on the growth side of healthcare, with exposure to some private investments. Private investments can be quite lucrative as it is participating before public launches that can see shares rise spectacularly. On the other side of this large potential is a highe...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA And Healthcare Dashboard For July

Genmab A/S (GMAB) Q1 2021 Earnings Conference Call May 05, 2021 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Wimal Kapadia - Bernstein Michael Schmidt - Guggenheim...

Genmab A/S (GNMSF) and Seagen (SGEN) announces that the U.S. FDA has accepted for Priority Review the Biologics License Application ((BLA)) seeking accelerated approval for tisotumab vedotin.This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recur...

The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...

Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q4 earnings call. For further details see: Genmab A/S 2020 Q4 - Results - Earnings Call Presentation